As one of the landmark events in progression of glioma, Isocitrate dehydrogenase type 1 (IDH1) mutations have been constantly studied as a potential therapeutic target, among which IDH1(R132H) is the most frequent one. This evidence concerns the gene IDH1 and central nervous system cancer.